Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) is a fast-growing cancer where the bone marrow makes abnormal myeloblasts, red blood cells, or platelets. These "leukemia cells" quickly crowd out healthy cells, leading to a high risk of infection, anemia, and easy bleeding.

When You Should Consider AML Evaluation

• Sudden bruising or tiny red spots on the skin called petechiae.

• Shortness of breath and extreme pale skin indicating anemia.

• Persistent fevers that do not respond to standard antibiotics.

• Evidence of high risk for infection or unexplained, easy bleeding.

Methods of AML Classification

• FLT3 Mutation: Found in about 30% of cases and usually requires specific targeted drugs.

• IDH1/IDH2 Mutations: Subtypes targeted by newer oral therapies.

• TP53 Mutation: Often indicates a more resistant form of the disease.

• APL (Acute Promyelocytic Leukemia): A unique, highly curable subtype treated with non-chemo drugs like arsenic trioxide.

• Secondary AML: Often found in older adults (60+) arising from previous blood disorders.

How AML Treatment Is Performed

• Induction Therapy: Typically a "7+3" regimen involving 7 days of one chemotherapy and 3 days of another to achieve complete remission.

• Consolidation (Post-remission): Additional chemotherapy or a Stem Cell Transplant to kill remaining microscopic cells.

• Targeted Therapy: Use of specific drugs for mutations like FLT3 or IDH1/IDH2.

• Low-Intensity Options: Use of Venetoclax pills or Hypomethylating Agents (HMA) like Azacitidine for patients who cannot handle high-dose chemo.

• Non-Chemo Regimens: Use of All-Trans Retinoic Acid (ATRA) specifically for the APL subtype.

Pre-Procedure Preparation

• Cytogenetic profiling to determine the specific genetic mutations and treatment plan.

• Assessment of age and physical tolerance for intensive chemotherapy.

• Evaluation of heart or kidney function to determine if low-intensity options like Venetoclax are necessary.

• Screening for previous blood disorders that may lead to secondary AML.

Tests Before AML Treatment

• Bone Marrow Analysis: To identify abnormal myeloblasts and clear the marrow of visible blasts.

• Genetic Testing: To check for FLT3, IDH1/IDH2, or TP53 mutations.

• Blood Counts: To assess the severity of anemia and low platelet levels.

• Cytogenetic Profiling: To map the "cytogenetic" profile which dictates the specific therapy.

Life After AML Treatment

• For younger adults (<60), the 5-year survival rate is roughly 40% to 50%.

• For older adults (60+), survival is lower, typically around 10% to 20%.

• Patients with the APL subtype enjoy an excellent cure rate of over 90%.

• Ongoing monitoring is required during the consolidation phase to prevent a relapse.

Benefits of AML Treatment

• Clears the blood and bone marrow of visible leukemia blasts.

• Provides "insurance" against relapse through consolidation or transplants.

• Offers improved survival for older patients through modern low-intensity pill combinations.

• Restores the production of healthy white blood cells, red cells, and platelets.